Restless Leg Syndrome

HORIZANT (gabapentin enacarbil) 600mg extended-release tablets by GlaxoSmithKline and XenoPort

FDA Announces Horizant 600mg Tablet Shortage

GlaxoSmithKline is currently experiencing a shortage of Horizant 600mg extended-release tablets, according to the FDA. Horizant is a prodrug of gabapentin that is indicated for postherpetic neuralgia and for moderate-to-severe primary restless legs syndrome in adults.

Two Drug Classes Found Effective for Restless Legs Syndrome

Two Drug Classes Found Effective for Restless Legs Syndrome

In patients with restless legs syndrome, dopamine agonists and calcium channel alpha-2-delta ligands are effective in reducing symptoms and improving sleep and quality of life, although adverse events are common and often lead to treatment withdrawals.

Neupro Now Available for Parkinson’s and Restless Leg Syndrome

UCB announced that Neupro (rotigotine transdermal system) is now available as a once-daily patch for the treatment of signs and symptoms of early and advanced stage idiopathic Parkinson’s disease (PD) and moderate-to-severe primary restless legs syndrome (RLS).

Neupro Approved for Parkinson’s and Restless Legs Syndrome

UCB announced that the FDA has approved Neupro (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson’s disease (PD) and as a treatment for moderate-to-severe primary restless legs syndrome (RLS).

HORIZANT (gabapentin enacarbil) 600mg extended-release tablets by GlaxoSmithKline and XenoPort

Horizant Approved for Restless Legs Syndrome

GlaxoSmithKline and XenoPort announced that the FDA has approved Horizant (gabapentin enacarbil extended-release tablets) for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults.